JFJean-Michel Fabre

Jean-Michel Fabre

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jean-Michel Fabre has a total of 83 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Survival after Multimodal Treatment Including Surgery for Metastatic Esophageal Cancer: A Systematic Review

    by Thomas Bardol, Lorenzo Ferre, Safa Aouinti, Marie Dupuy, Eric Assenat, Jean-Michel Fabre, Marie-Christine Picot, Regis Souche

    (1) Background: The management of metastatic esophageal cancer is more often limited to palliative chemotherapy. Limited data are available regarding the role of surgery that remains controversial. The aim of this systematic review is to assess the survival outcome of surgically treated metastatic esophageal cancer patients. (2) Methods: The present systematic review is designed using the PRISMA guidelines and has been registered with PROSPERO (CRD42019140306). Two reviewers independently searched and identified studies dealing with surgery for stage IV esophageal cancer in the Medline and Google Scholar databases between January 2008 and December 2019. (3) Results: Seven retrospective nonrandomized studies, totaling 1756 patients with stage IV esophageal cancer who underwent curative surgery, were included. Our analysis demonstrates a three-year overall survival rate of 23% (CI 95% 17–31) among patients undergoing surgery. Because only two comparative studies were identified, data compilation and relative risk evaluation through meta-analysis were not possible. (4) Conclusions: Multimodality treatment, including surgery in curative intent, seems associated with a significant chance of three-year overall survival. A prospective evaluation of this approach and validation of adequate selection criteria are needed.


  • Prospective, multicentric, comparative study between sleeve gastrectomy and Roux-en-Y gastric bypass, 277 patients, 3 years follow-up

    by J.-M. Catheline, M. Fysekidis, Y. Bendacha, J.-J. Portal, N. Huten, E. Chouillard, J. Gugenheim, G. Fourtanier, K. Arapis, S. Msika, et al.


  • Three year prospective study in morbidly obese patients between longitudinal gastrectomy and gastric bypass based on a composite outcome combining weight loss efficacy and surgery related complications (PHRC SLEEVE K060213 / IDRCB2007-A00373-50)

    by Jean Marc Catheline, Marinos Fysekidis, Yasmina Bendacha, Najib Bdeoui, Vidhya Raghavan, Sophie Gerard, Jean Jacques Portal, Rami Dbouk, Jean Michel Fabre, Gilles Fourtanier, et al.

    Since its first description in 2000, Longitudinal Gastrectomy (LG) has become the first surgical procedure in the treatment of morbid obesity in the world, exceeding in numbers Gastric Bypass (GB). GB is considered to have better results regarding long-term weight loss and improvement in co-morbidities. We aimed to demonstrate that LG is non inferior to GB for a composite end point that included more than 50% excess weight loss from the baseline and surgery related complications after a mean follow-up of 36 months. This is a prospective study in morbidly obese patients that tested a two hypotheses composite outcome: the first hypothesis was that after 36 months LG was non-inferior to GB regarding EWL (the predefined margin of non-inferiority was ±15%), and the second hypothesis was the presence of significant difference in post-operative morbidity and mortality. From February 2008 to March 2015 we included 277 patients (91 GB vs 186 LG). The mean age was 41.1 years, 19.2% had a previous bariatric operation, 85.9% were women and the average pre-intervention BMI was 45.3 kg/m2. At baseline there were no significant differences between the GB and LG for age, sex and BMI. The % of patients with EWL > 50% was at 18 months for 82.1% (GB) vs 84.5% (LG), and 79.1 vs. 79.5% respectively at 36 months. The estimated difference in EWL was [−10.5% to 9.8%], confirming the non-inferiority of LG compared to BP. Finally there was a significant less morbidity and mortality for the LG group (GB vs LG, 12.1 vs. 4.8%, one death for LG, P=0.01). This is the first prospective study demonstrating that LG is not inferior to GB for an estimated 10% difference in EWL but with less surgical complications. These results reinforce the choice of LG as surgical procedure for obesity.

  • Laparoscopic versus open distal pancreatectomy: a single-institution case-control study

    by Sanket Sharad Mehta, Ghalia Doumane, Thibault Mura, David Nocca, Jean-Michel Fabre


  • Chirurgie laparoscopique : les recommandations des sociétés savantes spécialisées en 2006, SFCL–SFCE

    by G. Champault, B. Descottes, J.-L. Dulucq, J.-M. Fabre, G. Fourtanier, B. Gayet, H. Johanet, G. Samama


  • Is laparoscopic left pancreatic resection justified?

    by J. M. Fabre, J. L. Dulucq, C. Vacher, M. C. Lemoine, P. Wintringer, D. Nocca, J. S. Burgel, J. Domergue

    We reviewed our experience of laparoscopic left pancreatectomy to establish the feasibility of this approach and the characteristics of the operating procedure. Thirteen patients with a mean age of 60 years were deemed for a left pancreatectomy. Preoperative diagnoses were: nine mucinous cystadenoma and one insulinoma, intraductal mucinous ectasia, chronic pancreatitis with ductal stenosis, and distal pancreatic tumor. Operative mortality was nil. Two patients required conversion for bleeding from splenic vein injuries leading to a splenectomy in one case. The spleen was preserved in 10 cases. Postoperative course was uneventful in nine cases. Four patients experienced postoperative complications: one pancreatic fistula, two liquid cysts on the pancreatic margin, and one reoperation for bleeding from a trocar port. Length of stay ranged from 5 to 22 days. These preliminary results confirm that in selected cases laparoscopic resection of the left pancreas is feasible and safe.


  • Nocardiosis revealed by thyroid abcess in a liver - kidney transplant recipient

    by Anne Vandôme, Georges Philippe Pageaux, Michael Bismuth, Jean Michel Fabre, Jacques Domergue, Colette Perez, Marc Makeieff, Georges Mourad, Dominique Larrey

    Nocardiosis is a life-threatening infection, particularly among immunocompromised patients, which usually affects lungs, skin and central nervous system. We report a case of disseminated nocardiosis revealed by suppurative thyroiditis in a liver-kidney transplant recipient with poor nutritional status at the time of infection. Nocardia Asteroides was isolated from fine-needle aspiration material of the thyroid abscess. Clinical manifestations resolved after surgical drainage of the thyroid abscess, prolonged antibiotherapy and diminution of immunosuppressive regimen. Clinicians should be aware of this entity, as Nocardia Asteroides may need more than 5 days of culture to be isolated.


  • The majority of liver transplant recipients with normal liver enzyme tests (LET) exhibit long term liver graft lesions

    by Michael Bismuth, Georges-Philippe Pageaux, Christophe Duvoux, Val\'Erie Costes, Elie-Serge Zafrani, Jean-Michel Fabre, Pierre Blanc, Daniel Cher-Qui, Jacques Domergue, Daniel Dhumeaux, et al.

  • Management of intraductal papillary mucinous tumours of the pancreas

    by Francis Navarro, Jacques Michel, Paul Bauret, Jeanne Ramos, Pierre Blanc, Jean Michel Fabre, Bertrand Millat, Bruno Desrousseaux, Jacques Domergue

    Objective: To focus attention on the management and outcome of patients with intraductal papillary mucinous tumours of the pancreas. Design: Retrospective study and analysis of published reports. Setting: University hospital, France. Subjects: 111 patients (101 published cases and our own 10 cases) divided in two groups: the first including malignant tumours (n = 46), and the second group benign or in situ tumours (n = 61). In 4 patients the type of tumour was not known. Main outcome measure: Resectability, mortality and recurrence. Results: More men had benign or in situ tumours [48/61 (79%) compared with 28/46 (61%), p = 0.054]. Pancreatitis was more common among benign than malignant tumours [34/61 (58%) compared with 21/46 (46%), p = 0.33]. In group I, 39 patients had diabetes. A total of 107 patients were operated on: pancreaticoduodenectomy (n = 54, 50%), distal pancreatectomy (n = 25, 23%), total pancreatectomy (n = 4, 4%), bypass (n = 2, 2%). The type of resection was not mentioned in 22 records (21%). Four patients were not operated on because of their poor general condition. The resectability rate was 98% (105/107). Eleven patients had died at the time of publication. Hospital mortality rate was 3% (n = 3), mainly because 2 of the 4 who had total pancreatectomy died. With a median follow‐up of 37 months, recurrence was 5% (n = 5). Conclusion: Intraductal papillary mucinous tumours of the pancreas are well known distinctive pancreatic tumours that are usually intraductal but may develop into invasive carcinoma. They should be resected, and have a good prognosis and low recurrence rate. Copyright © 1999 Taylor and Francis Ltd.


  • Experimental assessment of the risk of tumor recurrence after laparoscopic surgery

    by Marie-Christine Le Moine, Francis Navarro, Jean-St[Eacute]Phane Burgel, Andr[Eacute] Pellegrin, Abdel Raouf Khiari, Didier Pourquier, Jean-Michel Fabre, Jacques Domergue